News about Global Pharma

Celonic Group Signs Multi-Year Manufacturing Service Deal with LINDIS Biotech

Catumaxomab is a first-in-class, trifunctional bispecific monoclonal antibody designed for the intraperitoneal treatment of malignant ascites in adults with epithelial cell adhesion molecule (EpCAM)-positive carcinomas who are not eligible for other systemic anticancer therapy.

Global Pharma | 20/02/2025 | By Aishwarya |  343

Perceive Pharma Secures USD 15 Million in Series A Financing Round

Perceive Pharma is also pleased to announce that Carol Gallagher, Pharm.D. has joined the company's Board of Directors as an independent director.

Global Pharma | 19/02/2025 | By Aishwarya |  641

Rznomics Liver Cancer Drug RZ-001 Secures Fast Track Designation from US FDA

Rznomics' anticancer drug RZ-001 has received Fast Track Designation from the US FDA for the treatment of liver cancer – Hepatocellular Carcinoma (HCC), marking its second designation after Glioblastoma (GBM), to accelerate its clinical development.

Global Pharma | 19/02/2025 | By Abha |  312

VIVOZON Pharmaceutical Secures MFDS Approval for UNAFRA Inj.

With this milestone, UNAFRA Inj. has become the 38th innovative drug in Korea. UNAFRA Inj., discovered by using the company's proprietary multi-target drug development platform, is the world's first non-opioid, non-NSAIDS analgesic.

Global Pharma | 18/02/2025 | By Aishwarya |  373

Aveva Drug Delivery Systems Introduces Generic Fentanyl TDS in US

The launch of Fentanyl TDS, a prescription 3-day transdermal patch for managing moderate to severe chronic pain (generic equivalent to Duragesic®), required the rapid sourcing and seamless integration of advanced manufacturing equipment's with existing systems to meet regulatory and operational standards.

Global Pharma | 18/02/2025 | By Aishwarya |  202

Glenmark Pharmaceuticals Introduces Latanoprost Ophthalmic Solution

Glenmark’s Latanoprost Ophthalmic Solution, 0.005 percent (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan®2 Ophthalmic Solution, 0.005 percent of Upjohn US 2 LLC.

Global Pharma | 18/02/2025 | By Aishwarya |  310

Innate Pharma Secures FDA Granted BTD for Lacutamab

The BTD is granted based on Phase 1 study results as well as results from the Phase 2 TELLOMAK study, where lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome.

Global Pharma | 18/02/2025 | By Aishwarya |  318

3Z Pharmaceuticals Announces Publication of Transformative Study in Neuropsychopharmacology

3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as a foundation for a novel therapy for ADHD.

Global Pharma | 17/02/2025 | By Manvi |  313

Grindeks Continues to Strengthen its Global Presence by Entering New Export Markets

This year, for the first time, Grindeks products will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore, the Philippines, and most of Europe.

Global Pharma | 17/02/2025 | By Manvi |  258

IASO Bio Receives Hong Kong's DOH Acceptance of NDA for Equecabtagene Autoleucel

This treatment is indicated for patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapies.

Global Pharma | 17/02/2025 | By Aishwarya |  368